Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1/2 1

Status

Withdrawn 1Completed 1

Sponsor Class

OTHER 1NIH 1

Study Type

Interventional 2

Sponsor

Cancer Type

Dermatologic 2

Conditions

Leukemia 53Lymphoma 51Melanoma 44Breast Neoplasms 37Lymphoma, Follicular 36Leukemia, Myeloid, Acute 33Leukemia, Lymphocytic, Chronic, B-Cell 30Precursor Cell Lymphoblastic Leukemia-Lymphoma 29Lymphoma, Non-Hodgkin 29Neuroblastoma 28Multiple Myeloma 28Lymphoma, Large B-Cell, Diffuse 25Prostatic Neoplasms 23Lymphoma, Mantle-Cell 23Myelodysplastic Syndromes 22Lymphoma, Large-Cell, Immunoblastic 20Neoplasms, Plasma Cell 19Leukemia, Myeloid, Chronic-Phase 19Hodgkin Disease 18Carcinoma, Non-Small-Cell Lung 18Burkitt Lymphoma 18Ovarian Neoplasms 17Lymphoma, B-Cell, Marginal Zone 17Lung Neoplasms 17Neoplasm Metastasis 16Glioblastoma 16Leukemia, Myelogenous, Chronic, BCR-ABL Positive 15Congenital Abnormalities 15Leukemia, Myeloid, Accelerated Phase 14Gliosarcoma 12

Interventions

pembrolizumab 23Nivolumab 22aldesleukin 21Cyclophosphamide 20Ipilimumab 17Interleukin-2 17fludarabine 15fludarabine phosphate 14cemiplimab 12Radiotherapy 7Fluorouracil 7Dacarbazine 6binimetinib 5Vemurafenib 5Temozolomide 5Surgical Procedures, Operative 5Sirolimus 5Radiation 5Biopsy 5Aminolevulinic Acid 5encorafenib 4dabrafenib 4Photochemotherapy 4Educational Status 4trametinib 3sonidegib 3montanide ISA 51 3avelumab 3Tacrolimus 3Sodium Chloride 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Interventional × Skin Neoplasms × sargramostim × Clear all
NCT00019890 2024-03-04

Vaccine Therapy in Treating Patients With High-Risk Stage III or Completely Resected Metastatic Melanoma

National Cancer Institute (NCI)

Phase 2 Completed
Dermatologic

Melanoma, Neoplasms, Skin Neoplasms

NCT03282188 2018-05-04

REO13 Melanoma With of Without GM-CSF

University of Leeds

Phase 1/2 Withdrawn
Dermatologic

Melanoma, Skin Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡